A case of coronary artery disease with antiphospholipid syndrome that showed repeated stent thrombosis  by Mito, Takahiro et al.
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Summary  A  55-year-old  man  with  severe  chest  pain  was  hospitalized  for  acute  coronary  syn-
drome. Coronary  angiography  revealed  total  occlusion  of  his  left  anterior  descending  coronary
artery, which  was  successfully  recanalized  by  percutaneous  coronary  intervention  (PCI).  How-
ever, the  patient  subsequently  experienced  subacute  stent  thrombosis,  restenosis  in  the  stent,coronary
intervention;
Stent  thrombosis;
Acute  coronary
and frequent  thrombosis  in  PCI  toward  restenosis.  Primary  antiphospholipid  syndrome  should  be
considered  as  a  possible  cause  of  repeated  stent  thrombosis,  and,  if  salvage  by  PCI  is  impossible,
salvage by  coronary  artery  bypass  graft  should  be  considered.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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ntroduction
ntiphospholipid  syndrome  (APS)  is  deﬁned  clinically  by  the
resence  of  recurrent  arterial  and  venous  thrombotic  events
s  well  as  recurrent  pregnancy  loss,  and  serologically  by  a
ositive  test  for  antiphospholipid  antibodies  (i.e.  lupus  anti-
oagulant  (LA)  and  anticardiolipin  antibodies)  [1].  APS  is
ssociated  with  frequent  and  recurrent  thrombosis.  In  the
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oi:10.1016/j.jccase.2011.06.006resent  paper,  we  report  a  case  of  acute  coronary  syndrome
ACS)  with  APS  that  showed  repeated  subacute  stent  throm-
osis  (SAT)  after  percutaneous  coronary  intervention  (PCI)
oward  restenosis.
ase presentation
 55-year-old  man  had  hypertension,  dyslipidemia  and
urrent  smoking  as  coronary  risk  factors  and  had  been  diag-
osed  with  ACS  due  to  coronary  spasm  4  years  previously.
hereafter,  he  had  received  calcium  channel  blocker  and
icorandil.
 Published by Elsevier Ltd. All rights reserved.
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First hospitalization in our hospital for ACS
He  visited  our  hospital  because  of  sustained  chest  pain
accompanied  by  cold  sweat  and  back  pain.  He  experi-
enced  cardiopulmonary  arrest  with  ventricular  ﬁbrillation
(Vf)  soon  after  his  arrival,  and  recovered  to  sinus  rhythm
with  electrical  deﬁbrillation.  Electrocardiography  (ECG)
showed  ST  elevation  on  leads  V2—V5,  I,  and  aVL  (Fig.  1),
and  echocardiography  showed  hypokinesis  of  wall  motion
in  the  anteroseptal  area.  He  was  diagnosed  with  ACS
and  emergency  coronary  angiography  (CAG)  showed  that
the  mid  left  anterior  descending  coronary  artery  (LAD)
was  totally  occluded  with  thrombi  (Fig.  2A).  PCI  includ-
ing  thrombectomy  was  performed.  A  bare  metal  stent
(BMS,  driverTM 3.0  mm  ×  24  mm)  was  placed  across  the
lesion.  Angiography  after  stent  deployment  showed  com-
plete  expansion  of  the  stent  with  grade  3  Thrombolysis
In  Myocardial  Infarction  criteria  (TIMI)  ﬂow  (Fig.  2B).
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d elevation  in  leads  V2—V5,  I  and  aVL.
e  received  oral  aspirin  and  clopidogrel  and  intravenous
eparin.
On  hospital  day  4,  he  again  experienced  chest  pain  and
he  ECG  showed  ST  elevation  in  precordial  leads.  Emer-
ency  CAG  showed  that  the  distal  edge  of  the  stent  in  the
id  LAD  was  totally  occluded  with  thrombi  (Fig.  2C).  We
iagnosed  SAT  and  conﬁrmed  that  stent  apposition  was  opti-
al  and  moderate  plaque  remained  on  the  distal  edge  of
he  stent  as  assessed  by  intravascular  ultrasound  (IVUS).
 BMS  (S  stentTM 3.0  mm  ×  14  mm)  was  placed  across  this
istal  edge,  and  we  added  ballooning  to  a  2nd  diagonal
ranch  that  had  advanced  to  severe  stenosis  due  to  the
laque  shift.  The  ﬁnal  angiography  showed  complete  expan-
ion  of  the  stent  and  the  2nd  diagonal  branch  with  grade TIMI  ﬂow  (Fig.  2D).  Since  we  were  concerned  about  the
nsufﬁciency  of  antithrombotic  therapy,  we  replaced  heparin
ith  intravenous  argatroban,  and  clopidogrel  with  ticlopi-
ine  200  mg/day  and  cilostazol  200  mg/day  for  antiplatelet
e82  T.  Mito  et  al.
Figure  2  Results  of  coronary  angiography.  (A)  The  mid  left  anterior  descending  coronary  artery  was  totally  occluded  with  thrombi.
Arrow shows  total  occlusion.  (B)  The  coronary  ﬂow  in  the  left  anterior  descending  coronary  artery  showed  reperfusion  by  PCI.  (C)
The mid  left  anterior  descending  coronary  artery  was  totally  occluded  with  thrombi  at  the  distal  edge  of  the  stent.  Arrow  shows  total
occlusion. (D)  The  coronary  ﬂow  in  the  left  anterior  descending  coronary  artery  showed  reperfusion  by  PCI.  (E)  The  mid  left  anterior
descending coronary  artery  was  totally  occluded  with  thrombi  at  the  proximal  edge  of  the  stent.  Arrow  shows  total  occlusion.  (F)
The coronary  ﬂow  in  the  left  anterior  descending  coronary  artery  showed  reperfusion  by  PCI.
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therapy,  and  added  warfarin  and  bucolome  for  anticoagulant
therapy.
However,  on  hospital  day  5,  he  again  experienced  chest
pain  and  the  ECG  showed  ST  elevation  in  precordial  leads.
Emergency  CAG  showed  that  the  proximal  edge  of  the  stent
in  the  mid  LAD  was  totally  occluded  with  thrombi  (Fig.  2E).
We  diagnosed  a  recurrence  of  SAT,  and  performed  PCI.
Angiography  after  stent  deployment  showed  LAD  coronary
ﬂow  with  grade  3  TIMI  ﬂow  (Fig.  2F).  Follow-up  CAG  on  hos-
pital  day  22  showed  patency  of  the  stent  and  TIMI  3  ﬂow.
On  hospital  day  25,  he  was  discharged  in  stable  general
condition.
Next,  we  tested  whether  the  patient  was  allergic  to
the  stent  materials  (S-stentTM,  stainless  steel;  driverTM,
cobalt  alloy)  by  a  skin  patch  test,  and  he  showed  negative
responses.  A  decrease  in  platelet  values  that  would  have
suggested  heparin-induced  thrombocytopenia  (HIT)  was  not
observed.  Moreover,  we  measured  platelet  aggregability,
with  adenosine  5-diphosphate  and  collagen  as  agonists.  Con-
sequently,  aggregation  in  response  to  both  agonists  was
inhibited.  After  discharge,  we  measured  platelet  aggre-
gability  on  aspirin  100  mg/day  and  ticlopidine  200  mg/day
for  antiplatelet  therapy,  and  aggregation  in  response  to
both  agonists  was  again  inhibited.  The  values  of  protein-
S,  protein-C,  antithrombin  III,  antinuclear  antibody  and
others  were  within  normal  limits.  We  also  measured  anti-
cardiolipin  2-glycoprotein  I  complex  antibody  (anti-CL2
GPI-antibody)  and  LA,  and  considered  the  possibility  of  APS.
Consequently,  the  titer  of  anti-CL2 GPI-antibody  was  below
a  moderate  value  (99  percentile)  that  could  satisfy  the  lab-
oratory  criteria  for  APS  [2],  but  LA  was  positive  (anti-CL2
GPI-antibody  5.0  U/ml,  LA  1.54).  To  satisfy  the  standard  lab-
oratory  criteria  for  APS,  we  measured  LA  after  discharge
and  it  was  again  positive  for  LA  (2.43  and  1.94).  However,
we  could  not  exclude  the  possibility  that  LA  after  discharge
was  a  false-positive,  since  the  administration  of  warfarin
can  give  a  false-positive  for  LA  [3].  While  LA  was  initially
measured  before  the  administration  of  warfarin,  LA  was
measured  after  the  administration  of  warfarin  in  the  2nd  and
3rd  tests.  In  addition,  systemic  thrombosis  for  APS  showed
an  atypical  pattern  of  ‘‘stent  thrombosis’’.
We  discontinued  warfarin  3  months  after  the  1st  dis-
charge,  and  we  had  identiﬁed  that  platelet  aggregability
could  be  signiﬁcantly  inhibited  by  other  antithrombotic  ther-
apy  (aspirin,  ticlopidine  and  cilostazol).
Second hospitalization for post-infarction
angina
Four  months  after  the  1st  discharge,  he  was  admitted  to
our  hospital  again  because  of  chest  discomfort.  We  sus-
pected  post-infarction  angina,  and  CAG  showed  75%  in-stent
restenosis  in  the  mid  LAD  and  90%  stenosis  in  an  ostial  lesion
of  the  2nd  diagonal  branch,  and  other  coronary  arteries  did
not  show  any  signiﬁcant  change  (Fig.  3A).  We  diagnosed
that  restenosis  was  the  culprit  lesion  of  post-infarction
angina.  We  performed  plane  old  balloon  angioplasty  (POBA)
on  the  in-stent  restenosis  (ISR)  lesion,  and  identiﬁed  sufﬁ-
cient  expansion  of  the  lesion,  but  also  identiﬁed  haziness
in  the  lesion  (Fig.  3B).  We  applied  POBA  to  the  lesion  again,
and  haziness  in  the  lesion  disappeared.  However,  thrombosis
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ppeared  in  the  ostium  of  the  2nd  diagonal  branch  and  distal
AD  (Fig.  3C).  We  aspirated  in  the  LAD  with  a  thrombus  aspi-
ation  catheter,  and  the  thrombus  in  the  2nd  diagonal  branch
isappeared,  while  we  noted  total  occlusion  of  the  distal
AD  and  recurrence  of  the  above-mentioned  haziness  in  the
tent  (Fig.  3D).  Due  to  concerns  about  the  possibility  of  HIT,
e  discontinued  the  administration  of  intravenous  heparin
nd  started  the  administration  of  intravenous  argatroban.
hereafter,  we  repeated  POBA,  aspiration  of  thrombus  and
orceful  injection,  and  observed  almost  complete  disappear-
nce  of  the  haziness  in  the  stent,  but  the  total  occlusion  in
he  distal  LAD  and  2nd  diagonal  branch  remained  (Fig.  3E
nd  F).  We  maintained  the  activated  coagulation  time  (ACT)
onger  than  250  s,  and  a decrease  in  platelet  values  that
ould  have  suggested  HIT  was  not  observed.  In  addition,  a
est  for  HIT  antibody  was  negative.
hird hospitalization in our hospital for
ost-infarction angina
wo  months  after  the  2nd  discharge,  the  patient  was  again
dmitted  to  our  hospital  due  to  a  recurrence  of  chest  pain.
e  performed  elective,  which  showed  in-stent  total  occlu-
ion  in  the  mid  LAD,  the  restoration  of  coronary  ﬂow  in
he  2nd  diagonal  branch,  and  the  development  of  collateral
irculation  (Rentrop  classiﬁcation  2)  from  the  2nd  diago-
al  branch  to  the  distal  LAD  (Fig.  4A  and  B).  He  again
howed  a  positive  test  for  LA  without  the  administration  of
arfarin,  and  consequently  was  diagnosed  as  APS  with  fre-
uent  thrombosis.  If  he  was  treated  by  PCI,  the  lesion  was
ndicated  for  a  drug-eluting  stent  (DES).  However,  in  con-
olidating  APS,  the  use  of  a  DES  may  induce  more  frequent
tent  thrombosis  than  the  use  of  a  BMS  [4].  Based  on  the
revious  episode  of  thrombosis  with  the  PCI  technique,  we
udged  that  coronary  artery  bypass  graft  (CABG)  was  appro-
riate.  He  received  off-pump  CABG  (left  internal  thoracic
rtery  — LAD,  right  internal  thoracic  artery  —  2nd  diagonal
ranch).  During  and  after  the  operation,  there  were  no  sig-
iﬁcant  complications.  The  administration  of  warfarin  was
estarted  after  the  operation.  We  conﬁrmed  that  the  bypass
rafts  were  patent  by  coronary  CT,  and  he  was  discharged
n  the  6th  post-operative  day.
iscussion
e  have  reported  an  uncommon  case  of  CAD  with  APS,
nvolving  2  occurrences  of  in-stent  thrombosis  in  a  patient
ith  ACS  within  48  h,  which  included  frequent  thrombosis  in
CI,  and  total  in-stent  occlusion,  which  was  contra-indicated
or  PCI.
Schomig  et  al.  reported  that  the  frequency  of  in-stent
hrombosis  was  0.8%  [5],  Leon  et  al.  reported  a  value  of  0.6%
6],  and  the  j-Cypher  Registry  gave  values  of  0.47%  within
0  days,  0.74%  within  1  year  and  0.94%  within  2  years  [7].
hus,  the  frequency  of  in-stent  thrombosis  appears  to  be
ess  than  1.0%.  On  the  other  hand,  many  predictors  of  stent
hrombosis  have  been  identiﬁed,  such  as  under-expansion
f  the  stent,  discontinuation  of  antiplatelet  therapy,  insuf-
ciency  of  and  resistance  to  antithrombotic  therapy,  ACS,
esidual  dissection,  HIT,  platelet  activation  due  to  oper-
tional  invasion,  diabetes  mellitus  and  renal  failure.  In
e84  T.  Mito  et  al.
Figure  3  (A)  Coronary  angiography  showed  75%  in-stent  restenosis  in  the  mid  LAD  and  90%  stenosis  in  an  ostial  lesion  of  the  2nd
diagonal branch.  The  transparent  arrow  shows  in-stent  restenosis  in  the  LAD.  The  black  arrow  shows  stenosis  in  the  2nd  diagonal
branch. (B)  Coronary  angiography  after  POBA  of  the  ISR  lesion  showed  haziness  in  the  stent.  The  arrow  indicates  haze.  (C)  Coronary
angiography after  POBA  of  the  hazy  lesion  showed  the  disappearance  of  haziness  and  the  appearance  of  thrombosis  in  the  ostium  of
the 2nd  diagonal  branch  and  distal  LAD.  The  arrow  shows  thrombi  in  the  2nd  diagonal  branch.  The  circle  shows  thrombi  in  the  distal
LAD. (D)  Coronary  angiography  after  thrombus  aspiration  shows  the  disappearance  of  the  thrombus  in  the  2nd  diagonal  branch,
total occlusion  of  the  distal  LAD,  and  the  recurrence  of  haziness  in  the  stent.  The  arrow  shows  haziness.  The  circle  shows  thrombi
in the  distal  LAD.  (E)  Final  coronary  angiography  shows  the  disappearance  of  haziness  in  the  stent,  and  total  occlusion  in  the  distal
LAD (circle)  and  2nd  diagonal  branch  (arrow).  (F)  Final  coronary  angiography  shows  total  occlusion  in  the  distal  LAD  (circle).
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Figure  4  (A)  Coronary  angiography  shows  total  occlusion  in  the  stent  in  the  mid  LAD  (transparent  arrow)  and  the  restoration  of
coronary ﬂow  in  the  2nd  diagonal  branch  (black  arrow).  (B)  Coronary  angiography  shows  in-stent  total  occlusion  in  the  mid  LAD
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development of  collateral  circulation  (Rentrop  classiﬁcation  2)  
addition,  predictors  of  frequent  thrombosis  in  PCI  have  been
identiﬁed,  such  as  HIT,  resistance  to  and  insufﬁciency  of
antithrombotic  therapy,  and  the  inability  to  prolong  the  ACT
in  PCI.
In  this  case,  just  after  PCI  for  ACS,  the  administration
of  heparin  did  not  prolong  the  activated  partial  thrombo-
plastin  time  (aPTT).  First,  SAT  occurred,  and  therefore  we
initially  suspected  a  heparin  insufﬁciency.  Thereafter,  we
replaced  heparin  with  argatroban  and  prolonged  the  thera-
peutic  range  of  aPTT,  but  a  2nd  incidence  of  SAT  occurred.
We  could  not  explain  this  thrombosis  solely  based  on  the
insufﬁcient  prolongation  of  aPTT.  Moreover,  the  later  throm-
bosis  and  occlusion  in  the  stent  occurred  under  a  sufﬁcient
antiplatelet  effect,  stent  apposition,  prolonged  ACT  and
aPTT  in  PCI,  and  negative  HIT.  Therefore,  we  could  not  ini-
tially  explain  his  clinical  course.
Diagnosis of APS
In  this  case,  we  diagnosed  APS  at  the  3rd  admission.  When
we  considered  the  actual  classiﬁcation  criteria  [2],  his  data
were  consistent  with  the  clinical  criteria  ‘‘Arterial,  venous
or  small  vessel  thrombosis  in  any  tissue  or  organ,  to  be  con-
ﬁrmed  by  objective  validated  criteria’’  and  the  laboratory
criteria  ‘‘Lupus  anticoagulant  present  in  plasma’’.
In  this  case,  thrombosis  only  occurred  in  the  stent  and
the  branch  near  the  lesion,  and  did  not  occur  in  other  ves-
sels.  Therefore,  we  did  not  suspect  that  thrombosis  was
caused  by  APS.  Moreover,  since  the  patient  had  received
warfarin  for  a  while,  we  did  not  closely  examine  whether
the  results  of  the  follow-up  LA  test  were  actually  a  false-
positive.  Our  diagnosis  of  APS  may  have  been  delayed  due
to  this  confusion.Thrombosis in PCI
With  regard  to  the  stent  thrombosis  at  the  1st  admission,
it  has  been  reported  that  antiphospholipid  antibody  may
P
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o%  stenosis  in  the  2nd  diagonal  branch  (black  arrow),  and  the
 the  2nd  diagonal  branch  to  the  distal  LAD  (circle).
ontribute  to  early  stent  occlusion  [8].  In  particular,  it
as  been  reported  that  patients  with  coronary  artery
clerosis  with  systemic  lupus  erythematosus  (SLE)  and
ositive  antiphospholipid  antibody  with  a  DES  frequently
howed  thrombotic  occlusion  in  their  stents.  The  presence
f  antiphospholipid  antibody  and  the  delayed  formation  of
eo-intima  by  DES  had  also  been  discussed  [4].
With  regard  to  total  occlusion  in  the  stent  at  the  3rd
dmission,  we  suspected  that  this  was  more  likely  a  case
f  subacute  occlusion  than  acute  occlusion  based  on  the
ymptomatic  course  and  the  development  of  collaterals.
cclusion  occurred  where  we  had  identiﬁed  the  previous  ISR
nd  the  formation  of  thrombus  at  the  2nd  admission.  We  sus-
ected  that  re-restenosis  was  due  to  both  the  proliferation
f  intima  and  the  formation  of  thrombus.  The  antiprolifer-
tive  effect  of  antiphospholipid  antibody  on  intima  in  the
tent  has  been  reported  to  both  promote  atherosclerosis  [9]
nd  suppress  atherosclerosis  [10], and  thus  this  point  is  con-
roversial.  Therefore,  we  could  not  conclude  whether  APS
as  associated  with  the  repeated  ISR.  Since  coronary  risk
actors  were  adequately  controlled  and  the  patient  contin-
ed  to  take  his  medication  after  the  onset  of  AMI,  we  could
ot  identify  a  possible  cause  of  repeated  ISR  in  such  a  short
eriod  except  for  APS.
reatment of CAD with APS
he  algorithm  for  the  treatment  of  APS  reported  by  Lim
t  al.  is  very  useful  because  it  is  based  on  the  presently
vailable  evidence  [11]. In  a  case  of  recurrent  throm-
osis,  this  algorithm  recommends  treatment  consisting  of
‘Low-Molecular-Weight-Heparin  or  Unfractionated  Heparin
r  Warfarin  With  a  Higher  Target  INR  (INR  >  3.0)  or  Warfarin
lus  Antiplatelet  Agent.’’  In  this  case,  the  events  occurred
uring  periods  of  insufﬁcient  or  no  administration  of  war-
arin.  It  is  possible  that  none  of  these  events  may  have
ccurred  if  the  patient  had  received  sufﬁcient  warfarin.
eT
d
t
h
[
n
l
c
e
s
m
r
s
P
R
[
[86  
herefore,  we  should  reconsider  the  role  of  warfarin  in  the
evelopment  of  APS.
In  cases  of  CAD  with  APS  that  require  revasculariza-
ion,  we  waver  between  PCI  and  CABG.  Both  techniques
ave  been  reported  to  fail  in  association  with  thrombosis
8,12].  To  date,  there  are  few  case  reports  and  there  are
o  established  guidelines  regarding  the  method  for  revascu-
arization.  In  particular,  we  should  avoid  the  use  of  DES  in
ases  of  PCI  [4].  We  hope  that  treatment  guidelines  can  be
stablished  in  the  future,  based  on  a  consideration  of  cases
uch  as  this.
Finally,  this  case  raises  some  signiﬁcant  points  for  the
anagement  of  CAD  with  APS.  We  should  be  aware  of  the
ole  that  the  administration  of  warfarin  plays  in  APS  and
hould  choose  CABG  in  cases  that  are  contra-indicated  for
CI.
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